Monday, August 31, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 9, 2026

ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities

View original at finance.yahoo.com
“The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026.”
Verbatim excerpt from the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Following strong growth in 2025, ImmunityBio is focused on scaling in the U.S. and expanding across an increasing number of global markets

    60% confidence

  • ANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution

    60% confidence

  • Full enrollment of the pivotal BCG-naïve CIS trial with IDMC confirmation of adequate statistical power further strengthen the expanding body of clinical evidence supporting ANKTIVA in the NMIBC bladder cancer setting

    60% confidence

  • Supplemental BLA submission for BCG-naïve indication is on track for 2026

    60% confidence

  • The sustained momentum of ANKTIVA reflects its growing commercial adoption in the BCG-unresponsive NMIBC CIS setting and feedback from treating urologists has been consistently positive

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Hawkish Fed Signals at Jackson Hole Pressure Rate-Sensitive Assets
Kevin Warsh's hawkish inflation remarks at Jackson Hole, alongside a steady drumbeat of Federal Reserve testimony from Powell, Barr, Bowman and other officials on supervision, regulation and monetary policy, signal continued vigilance against inflation rather than an imminent easing cycle. Rate-sensitive and precious-metals-linked names such as SSR Mining sold off the same day, consistent with markets repricing for a firmer-for-longer policy stance.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,979
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,979 facts checked against source5,261 source documents archived
Query this data → isubstrate.com